Adam C. Yopp

16.9k total citations · 3 hit papers
217 papers, 10.0k citations indexed

About

Adam C. Yopp is a scholar working on Hepatology, Epidemiology and Oncology. According to data from OpenAlex, Adam C. Yopp has authored 217 papers receiving a total of 10.0k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Hepatology, 84 papers in Epidemiology and 80 papers in Oncology. Recurrent topics in Adam C. Yopp's work include Hepatocellular Carcinoma Treatment and Prognosis (92 papers), Liver Disease Diagnosis and Treatment (61 papers) and Pancreatic and Hepatic Oncology Research (51 papers). Adam C. Yopp is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (92 papers), Liver Disease Diagnosis and Treatment (61 papers) and Pancreatic and Hepatic Oncology Research (51 papers). Adam C. Yopp collaborates with scholars based in United States, Japan and Canada. Adam C. Yopp's co-authors include Amit G. Singal, Jorge A. Marrero, Nicole E. Rich, Neehar D. Parikh, John C. Mansour, Jasmin A. Tiro, Akbar K. Waljee, Jonathan S. Bromberg, Michael A. Choti and Sam C. Wang and has published in prestigious journals such as Cell, JAMA and Journal of Clinical Investigation.

In The Last Decade

Adam C. Yopp

203 papers receiving 9.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

2015 784 citations John C. Mansour, Adam C. Yopp et al. Nature Communications profile →
Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis

2018 770 citations Nicole E. Rich, Neehar D. Parikh et al. profile →
Intrahepatic Cholangiocarcinoma

2008 646 citations Mithat Gönen, Adam C. Yopp et al. profile →

Peers

Countries citing papers authored by Adam C. Yopp

Since Specialization

Citations

This map shows the geographic impact of Adam C. Yopp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam C. Yopp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam C. Yopp more than expected).

Fields of papers citing papers by Adam C. Yopp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam C. Yopp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam C. Yopp. The network helps show where Adam C. Yopp may publish in the future.

Co-authorship network of co-authors of Adam C. Yopp

This figure shows the co-authorship network connecting the top 25 collaborators of Adam C. Yopp. A scholar is included among the top collaborators of Adam C. Yopp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam C. Yopp. Adam C. Yopp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma 2026 ·Journal of Hepatology ·Adam C. Yopp, (unknown), (unknown), (unknown), (unknown), (unknown), Edward Cha, Stephen P. Hack, (unknown), Jessica Spahn, (unknown), (unknown), (unknown)	0
2	LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC) 2024 ·Annals of Oncology ·Adam C. Yopp, (unknown), Mingkai Chen, Ann‐Lii Cheng, Ahmed O. Kaseb, (unknown), Songbing Qin, Edward Cha, Stephen P. Hack, Qinshu Lian, (unknown), (unknown), Pierce K. H. Chow	35
3	Prognostic significance of real-world (RW) recurrence patterns after resection or ablation of early-stage hepatocellular carcinoma (HCC): Insights from the US Medicare population. 2024 ·Journal of Clinical Oncology ·Shishir K. Maithel, Rongrong Wang, Joanna Harton, Adam C. Yopp, Shimul A. Shah, Flavio G. Rocha, Sairy Hernandez, Spencer Cheng, Sarika Ogale, (unknown)	1
4	Presence of underlying cirrhosis is associated with increased in-hospital mortality and length of stay following pancreatoduodenectomy 2023 ·HPB ·(unknown), Gloria Chang, Matthew R. Porembka, John C. Mansour, Sam C. Wang, Patricio M. Polanco, Herbert J. Zeh, Adam C. Yopp	1
5	Multidisciplinary care for patients with HCC: a systematic review and meta-analysis 2023 ·Hepatology Communications ·(unknown), (unknown), Darine Daher, Nicole E. Rich, Ju Dong Yang, David Hsiehchen, Hao Zhu, Madhukar S. Patel, (unknown), Nina N. Sanford, Purva Gopal, Neehar D. Parikh, Adam C. Yopp, Amit G. Singal	44
6	IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) for adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in hepatocellular carcinoma (HCC) patients at high risk of disease recurrence after resection or ablation 2023 ·Journal of Hepatology ·Ahmed S. Kaseb, Minshan Chen, Pierce K. H. Chow, Masatoshi Kudo, Han Chu Lee, Adam C. Yopp, Lars Becker, Sairy Hernandez, Bruno Kovic, Qinshu Lian, (unknown), Lyndia C. Wu, Shukui Qin, Ann‐Lii Cheng	0
7	Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis 2021 ·Clinical Gastroenterology and Hepatology ·Nicole E. Rich, Samuel Phen, (unknown), (unknown), Adam C. Yopp, Ju Dong Yang, Jorge A. Marrero, Puneeth Iyengar, Rodney E. Infante, Amit G. Singal	28
8	Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis 2020 ·Gut ·(unknown), Purva Gopal, Nicole E. Rich, Adam C. Yopp, Takeshi Yokoo, Binu V. John, Jorge A. Marrero, Neehar D. Parikh, Amit G. Singal	105
9	Surgical management of hepatocellular carcinoma patients with portal vein thrombosis: The United States Safety Net and Academic Center Collaborative Analysis 2020 ·Journal of Surgical Oncology ·Emily L. Ryon, Joshua P. Kronenfeld, Rachel Lee, Adam C. Yopp, Annie Wang, Ann Y. Lee, (unknown), Cary Hsu, Eric J. Silberfein, Maria C. Russell, Neha Goel, Nipun B. Merchant, Jashodeep Datta	10
10	Hispanic/Latino Patients with Gastric Adenocarcinoma Have Distinct Molecular Profiles Including a High Rate of Germline CDH1 Variants 2020 ·Cancer Research ·Sam C. Wang, Yunku Yeu, Suntrea T.G. Hammer, Shu Xiao, Min Zhu, Changjin Hong, Jean R. Clemenceau, (unknown), Ibrahim Nassour, Jeanne Shen, (unknown), Scott I. Reznik, John C. Mansour, Adam C. Yopp, Hao Zhu, Tae Hyun Hwang, Matthew R. Porembka	21
11	Dissecting disease, race, ethnicity, and socioeconomic factors for hepatocellular carcinoma: An analysis from the United States Safety Net Collaborative 2020 ·Surgical Oncology ·Rachel Lee, Adriana C. Gamboa, (unknown), Adam C. Yopp, Emily L. Ryon, Joshua P. Kronenfeld, Neha Goel, (unknown), Ann Y. Lee, (unknown), Cary Hsu, Eric J. Silberfein, Shishir K. Maithel, Maria C. Russell	7
12	Mitotic regulators and the SHP2-MAPK pathway promote IR endocytosis and feedback regulation of insulin signaling 2019 ·Nature Communications ·Eunhee Choi, Sotaro Kikuchi, Haishan Gao, (unknown), Ibrahim Nassour, Adam C. Yopp, Amit G. Singal, Hao Zhu, Hongtao Yu	69
13	The Yield of Staging Laparoscopy in Gastric Cancer is Affected by Racial and Ethnic Differences in Disease Presentation 2017 ·Annals of Surgical Oncology ·Ibrahim Nassour, Hannah Fullington, Linda S. Hynan, Adam C. Yopp, Mathew M. Augustine, Patricio M. Polanco, Michael A. Choti, John C. Mansour, Sam C. Wang, Matthew R. Porembka	18
14	Failure Rates in the Hepatocellular Carcinoma Surveillance Process 2012 ·Cancer Prevention Research ·Amit G. Singal, Adam C. Yopp, Samir Gupta, Celette Sugg Skinner, Ethan A. Halm, (unknown), Mahendra Nehra, William M. Lee, Jorge A. Marrero, Jasmin A. Tiro	157
15	Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response 2011 ·Annals of Surgical Oncology ·Adam C. Yopp, Lawrence H. Schwartz, Nancy E. Kemeny, David H. Gültekin, Mithat Gönen, Zubin M. Bamboat, Jinru Shia, Dana Haviland, Michael I. D’Angelica, Yuman Fong, Ronald P. DeMatteo, Peter J. Allen, William R. Jarnagin	66
16	Randomized clinical trials in surgical oncology 2010 ·Adam C. Yopp, Ronald P. DeMatteo	1
17	Lymph Node Occupancy Is Required for the Peripheral Development of Alloantigen-Specific Foxp3 + Regulatory T Cells 2005 ·The Journal of Immunology ·Jordi Ochando, Adam C. Yopp, Yu Yang, Alexandre Garin, Yansui Li, Péter Boros, Jaime Llodrá, Yaozhong Ding, Sérgio A. Lira, Nancy Krieger, Jonathan S. Bromberg	157
18	FTY720-Enhanced T Cell Homing Is Dependent on CCR2, CCR5, CCR7, and CXCR4: Evidence for Distinct Chemokine Compartments 2004 ·The Journal of Immunology ·Adam C. Yopp, Shuang Fu, (unknown), Gwendalyn J. Randolph, Yaozhong Ding, Nancy Krieger, Jonathan S. Bromberg	60
19	FTY720 stimulates multidrug transporter– and cysteinyl leukotriene–dependent T cell chemotaxis to lymph nodes 2003 ·Journal of Clinical Investigation ·(unknown), Shuang Fu, Xia Mao, Adam C. Yopp, Michael D. Gunn, Gwendalyn J. Randolph, Jonathan S. Bromberg	107
20	Leukotrienes, Sphingolipids, and Leukocyte Trafficking 2003 ·The Journal of Immunology ·Adam C. Yopp, (unknown), Jonathan S. Bromberg	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact